Leukemia, Myelodysplasia, Transplantation
STOCKHOLM, SWEDEN – A novel CAR T construct was effective for children with ALL in relapse after CD19-directed CAR T therapy.
The drug is indicated for patients with CLL or SLL, with or without 17p deletion, who have had at least one prior therapy.
CHICAGO – The drug combination was evaluated in a phase 2 study of patients with previously untreated CLL.
CHICAGO – The study sheds light on the value of transplant after treatment with CAR T cells.
Ivosidenib is "likely to become the new standard of care treatment" for patients with IDH1-mutant relapsed-refractory AML.
The Food and Drug Administration has granted priority review to Astellas Pharma’s gilteritinib.
More than 8 in 10 youth were still alive and free of disease 4 years after starting combinations of methotrexate and/or nelarabine with chemo.
PITTSBURGH – With better therapy and supportive care, prospects for children with Down syndrome and standard risk ALL have improved in recent...
From the Journals
The long-term findings don’t raise red flags about safety with the drug in CLL.
Newer therapies and accurate predictive models will be key to treating elderly patients with AML.